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Technological advances and a greater degree of inter-laboratory co-operation mean that
genome-wide analyses can now be used to identify genetic variants that are robustly
associated with the risk of developing psychiatric and neurological disorders. In contrast
to the candidate gene approach, such screens may identify variants within genes which
have a hitherto unappreciated role in disorder pathogenesis, and whose brain function
is obscure. In this Perspective, I discuss how the behavioral functions of such genes
may be investigated using model systems, drawing attention to the potential caveats
and limitations with such approaches. The power of focused cross-species studies needs
to be effectively exploited to enable useful insights into the molecular pathogenesis of
common and disabling disorders, and ultimately to provide better clinical outcomes for
patients.
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GENOME-WIDE SCREENS IN PSYCHIATRY
More effective genotyping techniques,greater inter-laboratory col-
laboration (therefore larger pooled sample sizes), andmore precise
diagnostic/phenotyping strategies, now permit the identiﬁcation
of robust novel candidate genetic loci for vulnerability to common
and disabling psychiatric/neurological disorders using genome-
wide screens (GWS; Lee and Lupski, 2006; Cichon et al., 2009).
Contemporary psychiatric GWS comprise three types: genome-
wide association (GWA), copy number variant (CNV), or linkage.
In GWA studies, up to 2.5 million single nucleotide polymor-
phisms (SNPs) spanning the entire genome may be genotyped
in several thousand matched cases and controls. Allelic variants
that are more common in cases than in controls are consid-
ered to be “associated” with the disorder; these variants may
have functional consequences themselves, or alternatively, may
be in high linkage disequilibrium (LD) with functional variants
(Cichon et al., 2009). Most variants identiﬁed by GWAS to date
have relatively small effects on risk, although they may be com-
mon within the population. In CNV studies, genotyping arrays
are used to identify larger chromosomal segments that are either
disproportionately frequently duplicated or deleted in cases rel-
ative to controls; these mutations tend to be relatively rare, but
can exhibit large effects (Lee and Lupski, 2006). Linkage stud-
ies, in which selected regions of the genome are genotyped in
order to analyze co-segregation with disorder-associated pheno-
types, are less fashionable (reﬂecting the difﬁculty of obtaining
family-based samples), but can be performed as a prelude to iden-
tifying a candidate genomic region prior to more comprehensive,
directed association analyses (Yang et al., 2011). The lack of suc-
cess of the linkage-based approach to psychiatric illness to date
has suggested that such disorders are not caused by few, highly
penetrant transmitted mutations, but rather by many transmit-
ted variants of small effect, or by de novo mutations of large
effect.
Genome-wide screens have now been performed for sev-
eral psychiatric/neurological conditions. Studies on schizophrenia,
bipolar disorder, and Alzheimer’s disease for which large, well-
annotated sample collections are available have been the most
fruitful (Hardy and Williams, 2010; Doherty et al., 2011; Ripke
et al., 2011; Sklar et al., 2011), whilst lower-powered studies on
disorders such as attention deﬁcit hyperactivity disorder (ADHD)
have failed to identify robust candidate gene variants (Neale
et al., 2010) but have highlighted genomic regions which when
perturbed may inﬂuence vulnerability (Williams et al., 2010).
Although the biological functions of some signiﬁcant GWAS gene
hits are known a priori, e.g., the vesicular role of the protein
encoded by PICALM identiﬁed in a recent GWAS in patients
with Alzheimer’s disease (Harold et al., 2009), often the precise
role of the gene products in the brain is unclear. For genes such
as ZNF804A, identiﬁed in a GWAS of patients with schizophre-
nia/schizoaffective disorder (O’Donovan et al., 2008), functional
annotation is almost completely absent. Most CNV studies have
highlighted the involvement of genomic regions spanning mul-
tiple genes, the functions of which may often be unknown, and
not all of which may contribute to disorder phenotypes. Once a
poorly characterized candidate gene is identiﬁed from a GWS (as
many more will be in the near future), a key objective should be to
examine its normal function. Understanding the behavioral effects
of such genes will be critical given that psychiatric disorders are
diagnosed according to behavioral criteria andprior to the identiﬁ-
cation of any overt pathophysiology. Although human studies can
provide tantalizing insights into the functions of putatively path-
ogenic genetic variants (Walters et al., 2010; Esslinger et al., 2011;
and will continue to do so with increased accessibility to emerg-
ing technologies such as genome sequencing, Singleton, 2011; and
genetic neuroimaging,Linden andThome,2011), such approaches
are necessarily correlative, hampered by ethical/recruitment con-
straints, and potentially confounded by medication effects. Here,
www.frontiersin.org December 2011 | Volume 2 | Article 89 | 1
Davies Functions of psychiatric candidate genes
investigations in model systems, where direct links between geno-
type and brain function can be explicitly established, will be of
beneﬁt. Selecting the most appropriate model system and analyti-
cal tools will be crucial to understanding the behavioral pathology
of brain disorders.
CHOOSING A MODEL SPECIES
The genomes of organisms such as C. elegans and Drosophila
may be experimentally manipulated to investigate developmental
effects on primitive nervous systems, and such studies may have
relevance for human brain disorders (Kretzschmar, 2005;Wu and
Luo, 2005). However, humans and other mammals are more alike
both in terms of their genetic complement, and in terms of their
basic structural/functional brain homology; as such, this latter
group may represent the best type of model for understanding
complex psychiatric genetic phenomena. For the past quarter of a
century, mice have been the model of choice for investigating the
role of genetics in mammalian behavior (Kendler and Greenspan,
2006); they can be produced/maintained in large numbers on con-
sistent genetic backgrounds, and are amenable to neurobehavioral
analysis. However, mice are sub-optimal for techniques such as
neurosurgery and electrophysiology due to their small size; here,
rats are of greater use. As a consequence of their longer history
as an experimental model in behavioral neuroscience, the neuro-
biology of the rat is better deﬁned than that of the mouse, and
there are currently more behavioral paradigms available for this
species. Moreover, recent breakthroughs in genetic engineering
technology mean that the rat is now amenable to genetic manip-
ulation to some extent (Jacob et al., 2010). Whichever rodent
model is chosen, there are a number of caveats that should be
taken into consideration when modeling human disorders: ﬁrst,
whilst the rodent andhumangenomes are structurally similar, they
do differ signiﬁcantly in their regulation, expression, and post-
transcriptional modiﬁcation, exempliﬁed by species’ differences
in X-inactivation (Okamoto et al., 2011). Also, most experimen-
tal rodents are maintained on an inbred background to ensure
homozygosity at every genetic locus (and homogeneity of phys-
iology). In contrast, humans are generally outbred and show
substantial allelic variability. Hence, genetic backgrounds could
differentially modify the effect of the gene under investigation
across species. The use of recombinant inbred strains (including
genetic reference panels), which possess a level of genetic,molecu-
lar, and cellular complexity matching that of human populations,
has been important for identifying genetic loci for complex traits
and for testing experimental predictions in a manner more rel-
evant to human disease (Williams, 2009). Second, rodents and
humans differ in terms of their brain size, structure, complex-
ity, and associated behavioral functions (Kesner and Churchwell,
2011). Third, in the laboratory, rodents are maintained in small
same-sex groups and are often behaviorally tested during the day;
in the wild, the sexes are free to interact and are nocturnal. Hence,
in terms of social and circadian behaviors, laboratory rodents may
not even resemble those living wild, much less humans. Finally,
one rodent model cannot recapitulate every key aspect of a multi-
factorial psychiatric disorder, and nor is it necessarily the case that
any onemodel will exhibit behavioral features speciﬁc for one dis-
order. Despite these caveats, research in rodents has substantially
illuminated the neural basis of psychiatric phenotypes in humans,
and has led to signiﬁcant advances in treatment (McArthur and
Borsini, 2008).
CHOOSING A SPECIFIC GENETIC MODEL
As genetic manipulation in rats is in its infancy, I have lim-
ited my discussion to mouse models; undoubtedly, equivalent rat
models will shortly come online. In humans, SNPs may confer
risk through a variety of mechanisms: abrogating gene func-
tion (nonsense mutation), inducing subtle increases or decreases
in gene expression, inﬂuencing the ﬁdelity of splicing mech-
anisms and/or post-transcriptional stability, disrupting protein
structure/function (mis-sense mutation), affecting the availabil-
ity/strength of protein-binding sites or through inﬂuencing
genomic structure. Deletion CNVs typically act to eradicate the
function of multiple genes, whilst duplication CNVs cause over-
expression of multiple genes; both types of CNV may also disrupt
the function of adjacent genes through altering local chromatin
structure. The particular mouse model to be used may be chosen
according to the proposed mechanism of action of the “patho-
genic” variant in humans. Mutations eliciting subtle effects on
gene expression (and therefore behavior) are currently relatively
difﬁcult to induce and characterize in rodents. Therefore, models
possessing relatively gross changes in gene function, and exhibit-
ing larger effects on brain and behavioral functions, have been, and
will probably continue to be, themost practical short-term option.
Gene-deletion models may be most appropriate for examining
the neurobiological effects of nonsense mutations, expression-
reducing variants or deletionCNVs,whilst transgenicmice (which
possess a copy of the gene of interest inserted into the genome, ide-
ally at a known site, and thus over-express the gene), may be more
relevant to understanding the processes mediated by expression-
enhancing variants and duplication CNVs. In order to specify
which gene(s) perturbation within a CNV may be pathogenic,
a systematic analysis of lines of mice, each with an inactivating
mutation in a CNV gene (in the case of deletion CNVs), or lines
of mice, each transgenic for one CNV gene (in the case of dupli-
cation CNVs), may be undertaken. Large-scale knockout screens
(see below) should soon render the former approach achievable.
The functional consequences of many human SNPs will not
be obvious. As a default option, understanding the normal func-
tion of a candidate gene may be done in “gene-deletion” models
(where wildtype mice possessing two functional alleles of the
gene are compared to heterozygotes possessing one functional
allele and homozygotes possessing no functional alleles). Tra-
ditionally, homologous recombination has been used to create
targeted deletions in genes of interest; in conventional “knockout”
mice, the function of a critical exon is disrupted from conception,
so that homozygous mutants are deﬁcient for the gene product
throughout life. Multi-national collaborations [the International
Knockout Mouse Consortium (IKMC)1 and the International
Mouse Phenotyping Consortium (IMPC)2], have recently been
established with the goals of knocking-out and summarily charac-
terizing the vast majority of genes in the mouse genome over the
1http://www.knockoutmouse.org
2www.mousephenotype.org
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next few years. Knockout rodents can also be generated as so-called
“conditional forms”whereby the gene of interest is deleted at par-
ticular developmental timepoints, or in particular brain regions
(Morozov, 2008). Suchmodels permit researchers to identifywhen
and where a given gene product exerts its phenotypic effects and
may be particularly informative for understanding the pathogen-
esis of developmental or degenerative conditions. Other models
of value for the ﬁeld of psychiatric genetics include: mice with
deﬁned point mutations in loci of interest originally induced by
the chemical mutagen N -ethyl-N -nitrosourea (ENU; Acevedo-
Arozena et al., 2008), mice with chromosomal anomalies (Davies
et al., 2009; Trent et al., 2011), and inbred mice with spontaneous
mutations in genes of interest (Clapcote and Roder, 2006; Ishizuka
et al., 2007).
Each genetic mouse model has its own merits and limita-
tions: molecular constructs for generating knockout mice may be
time-consuming to synthesize, and in some cases, genes may not
amenable tohomologous recombination (e.g., those on theY chro-
mosome). However, knockout mice are generally easy to genotype
and breed provided that the gene-deletion does not deleteriously
affect sexual behavior/fertility. Inbred strains are readily available,
but one must rely on naturally occurring polymorphisms in genes
of interest. With ENU mutagenesis, it is possible to create point
mutations in sub-genetic sites of interest (e.g., within particular
exons or promoter regions) which may cause relatively subtle dis-
ruption to gene function; however, non-speciﬁcmutations need to
be eradicated by repeatedly breeding to a suitable strain, a costly,
labor-intensive process requiring large numbers of mice. Identify-
ing the pathogenic SNP from several in high LD represents amajor
challenge in human psychiatric genetics. Through using multi-
ple lines of ENU mutants, each with a discrete point mutation
within the orthologous LD region, it may ultimately be possible
to decipher the causal variant(s). Mice with gross chromosomal
mutations may be useful for modeling chromosomal abnormal-
ities with associated neurobehavioral phenotypes (including cer-
tain sex chromosome ploidies,Davies, 2011), or the effects of large
CNVs, but these mice often have perturbed expression of multi-
ple genes with pleiotropic effects, and therefore cannot provide
data on the inﬂuence of individual genes. Moreover, generating
mice with targeted gross chromosomal manipulations, although
possible (O’Doherty et al., 2005), is technically demanding.
Once a particular genetic model has been selected, to limit
unnecessary animal usage initial studies should focus on one sex
and one age-point at which signiﬁcant effects are most likely to
be identiﬁed; positive effects may then be further characterized in
the opposite sex, at different age-points, and in different strains.
Where a candidate gene/region associated with a “neurodevelop-
mental” disorder is manipulated, ﬁrst studies might be limited to
male mice, as these disorders tend to be more prevalent and/or
more severe in this sex; conversely, for later-onset “affective” dis-
orders, ﬁrst studies should be performed in female mice, as these
disorders tend to be more prevalent and/or more severe in this sex
(Rutter et al., 2003).Whether theoriginal association is sex-speciﬁc
may also inform what sex of model to use initially, e.g., associa-
tion between SNP rs7597593 within ZNF804A and schizophrenia
is apparently driven primarily by association in female patients
(Zhang et al., 2011) so examining the speciﬁc effects of Zfp804a
inactivation/overexpression in female mice may be a useful pre-
cursor to studying effects in males. Female rodents are generally
avoided in behavioral studies due to the potentially confound-
ing effects of their cyclic hormonal variations. However, there is
an increasingly recognized need for pre-clinical behavioral stud-
ies to examine females (not least to provide better predictive data
for translational pharmacological studies), and provided varia-
tions in hormone levels are co-varied for (e.g., by monitoring
estrus status), or completely removed (e.g., through ovariectomy),
such studies will be worthwhile. In terms of age, mice with muta-
tions of developmental disorder-associated candidate genes might
be behaviorally characterized at earlier timepoints than mice
with mutations of later-onset “affective” disorder-associated can-
didate genes; mice with mutations in neurodegenerative disorder-
associated candidate genes (e.g., Picalm) should be examined into
old age, cost implications notwithstanding.
CHOOSING A BATTERY OF BEHAVIORAL TASKS
A number of fundamental physiological measures should ﬁrst
be obtained in mutant animals; theoretically, risk variants could
inﬂuence vulnerability via non-speciﬁc effects during early pre-
and post-natal life. Basic measures might include: indices of gross
embryonic/extra-embryonic development, the time of occurrence
of developmental milestones in utero and postnatally, mortal-
ity/morbidity rates for individual genotypes in utero and post-
natally (to resolve whether the gene is having an important devel-
opmental role, and to determine the extent to which surviving
subjects represent a selected sub-population), interactions with
the dam/siblings, bodyweight, and grossmotor function. A second
level of assays could then be employed; these may provide data of
relevance to a particular disorder, and additionally, may help to
unconfound the results of any subsequent behavioral analyses.
Such assays may include tests of sensory, circadian, and consum-
matory functions, locomotor activity, assays of reactivity tonovelty
and exploration, tests of fear and anxiety, and paradigms tax-
ing motivation. Several of the “primary” and “secondary” assays
listed above will be performed routinely in the phenotyping screen
undertaken by the IMPC.
The behavioral assays to be used in the third tier of analy-
sis should be guided principally by the core symptoms of the
particular disorder(s) associated with the candidate variant. Obvi-
ously, human-speciﬁc constructs such as “theory of mind” cannot
be effectively modeled in rodents. However, there are now many
behavioral paradigms available for rodents which examine senso-
rimotor, social, and cognitive behaviors, including those relevant
to autism (Silverman et al., 2010). Many rodent cognitive tasks
are based on analogous human tasks used in the clinic, and gen-
erate data with signiﬁcant cross-species translatability (Humby
et al., 1999; Winstanley et al., 2006; Zeeb et al., 2009; Bussey
et al., 2011). Ideally, as many as possible of the core symptoms
of the associated disorder should be assessed in the genetic model;
assays should not be limited to those that are “easiest” to perform,
most commonly used or already established in the laboratory,
and, where necessary, appropriate collaborations should be ini-
tiated. It is surprising that many rodent models with disruptions
in putative ADHD-associated genes, are only tested for one (non-
speciﬁc) core feature of the disorder (hyperactivity) and not for
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the other core features of attentional or impulsive dysfunction,
despite the fact that assays of attention and impulsivity can now
be performed routinely (Humby et al., 1999; Isles et al., 2003;Win-
stanley et al., 2006; Humby andWilkinson, 2011).Where possible,
multiple assays should be used to obtain converging evidence for
effects on behavioral functions.
Once a robust behavioral phenotype has been established
and speciﬁed, its physiological, cellular, and molecular under-
pinnings can be investigated in detail and manipulated phar-
macologically. A number of additional manipulations examining
the inﬂuence of putative “environmental” protective/risk factors
for the disorder of interest on the behavioral phenotype may
be performed; such manipulations might include administra-
tion of established/experimental therapeutic drugs, acute/chronic
stress, altered housing/social conditions, dietary perturbations,
environmental enrichment, or in utero/postnatal exposure to
toxins.
Studying relatively simple models such as rodents with muta-
tions in single candidate genes will be useful for understanding
the role of those speciﬁc genes in basic mammalian brain develop-
ment/function, and for highlighting molecular and neural path-
ways of interest. However, by themselves, such studies will not
fully explain the pathogenesis of complex psychiatric disorders
which often exhibit symptoms unique to humans. A major chal-
lenge in the near future will be to produce more elegant models
which more faithfully mimic the constellation of behavioral, neu-
robiological, and molecular pathologies seen in brain disorders
(i.e., improved face validity). This could theoretically be done by
generating and examining mice with mutations in multiple con-
ﬁrmed candidate genes whose effects mirror those of the putative
pathogenic variants in humans (i.e., improved construct valid-
ity); such mice could then be exposed to environmental factors of
relevance to the pathogenesis of the disorder. A conceptually sim-
ilar approach has already been taken for some neurodegenerative
conditions with promising results (Lewis et al., 2010).
CONCLUSION
Genome-wide screens are highlighting more genetic variants
involved in the pathogenesis of psychiatric/neurological disorders.
Many of these are within genes of obscure function. Genetically
amenable rodent models, despite their limitations, will be of value
in understanding the pathways through which risk variants may
inﬂuence vulnerability to disorders of the brain, and hence in
identifying novel therapeutic targets. They will also be of use in the
systematic examination of how environmental risk factors interact
with genetic predispositions to affect behavioral phenotypes. Stud-
ies in rodentmodels should allowpsychiatrists to better predict the
behavioral repertoire, clinical course, and response to treatment of
patients possessing particular genetic risk variants.
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